>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • UPST +26.2%, LUMN +24.6%, VCYT +22%, TBLA +19.2%, INGN +18.8%, SHOP +18.5%, ACMR +17%, FTNT +16.4%, RUN +14.5% (also announces partnership with Tesla Electric), CEVA +11.6%, GO +11.1%, DT +11.1%, CRUS +11%, PAYO +10.5%, ZLAB +10.4%, ALTM +10.2%, PARR +9.6%, VFC +9.4%, RVLV +9.3%, CART +8.7%, GPN +8.6%, HALO +8.3%, VTEX +8%, RPD +7.8%, SMWB +7.6%, AAOI +7.5%, PRKS +7.1%, SWTX +6.9%, VSTS +6.8%, TH +6.7%, INSP +6.5% (also authorizes new $150 mln share repurchase program), AXON +6.1%, GMED +5.7%, OSUR +5.3%, EXEL +5.2% (also authorizes new $500 mln share repurchase program), NI +5.2%, BGNE +5.1%, ANDE +4.8%, AVA +4.8%, ADV +4.7%, LRN +4.6%, WIX +4.5%, IFF +4.4%, COOK +4.4%, TNGX +4.3%, PLTK +4%, SONY +3.9%, MDGL +3.9%, OSCR +3.8%, DO +3.7%, PR +3.5%, WYNN +3.5%, EGY +3.4%, RLAY +3.1%, MXCT +3.1%, ILMN +3%, ARKO +3%, AGL +2.9%, ORA +2.9%, OCUL +2.9%, ALAB +2.8%, WTI +2.8%, HL +2.7%, DVN +2.4%, ATGE +2.4%, CIM +2.4%, REAX +2.4%, GEO +2.3%, ENOV +2.1%, ENLT +2.1%, TGI +2%, WWW +2%, EXTR +1.9%, AZPN +1.7% (also to reduce workforce by 5%; authorizes up to $100 mln for repurchases), EFC +1.7%, NYT +1.7%, DVAX +1.5%, HMC +1.5%, ZBH +1.5%, IAC +1.4%, NHI +1.3%, BWIN +1.3%, EDIT +1.3%, RDDT +1.2%, GCT +1%, VERX +1%
Other news:
  • GTHX +66.1% (G1 Therapeutics and Pharmacosmos A/S have entered into a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for $7.15/ share in cash for a total equity value of ~$405 mln)
  • SWIM +13.8% (acquires Coverstar Central)
  • SWI +12.8% (to join S&P SmallCap 600)
  • EHTH +11.3% (CEO to retire)
  • AGIO +9.8% (to receive $1.1 bln in milestone payments following FDA Approval of Vorasidenib)
  • CRVS +7.7% (files $200 mln mixed shelf securities offering)
  • PNTG +6.5% (files mixed shelf securities offering)
  • ADCT +4.8% (files $300 mln mixed shelf securities offering)
  • RPTX +4.6% (files $350 mln mixed shelf securities offering)
  • RXRX +4.2% (Genentech exercises option for the first Neuroscience Phenomap)
  • VOD +3.6% (announces €500 mln share buyback program to commence)
  • OCUL +2.9% (received a written response from the U.S. FDA that the Phase 3 SOL-R clinical trial is appropriate for use as the Company's second adequate and well controlled study of AXPAXLI for the treatment of patients with wet age-related macular degeneration)
  • RKLB +2.4% (partners with Kongsberg Satellite Services)
  • BLNK +1.9% (announces strategic agreement with EVSTAR)
  • NOG +1.5% (increases dividend)
  • BTBT +1.4% (July production update)
  • NGNE +1.3% (NGN-401 received Regenerative Medicine Advanced Therapy designation from the U.S. FDA for the treatment of Rett syndrome)
Analyst comments:
  • ACA +2.7% (upgraded to Overweight from Equal-Weight at Stephens)
  • BLDR +2.7% (upgraded to Outperform from Neutral at Robert Baird)
  • VRT +2.4% (upgraded to Outperform from Neutral at Mizuho)
  • ARM +2.2% (upgraded to Mkt Perform from Underperform at Bernstein)
  • BNTX +2.1% (upgraded to Buy from Hold at Deutsche Bank)
  • MRNA +1.8% (upgraded to Hold from Sell at Deutsche Bank)